Single dose recombinant human erythropoietin reduces transforming growth factor beta in patients on chronic haemodialysis.
Arch Physiol Biochem
; 106(4): 265-8, 1998 Oct.
Article
en En
| MEDLINE
| ID: mdl-10417853
Short-term effects of recombinant human erythropoietin on serum levels of transforming growth factor beta-1, interleukin 1-alpha, interleukin 3, interferon gamma, and tumour necrosis factor alpha in patients with chronic renal failure on chronic haemodialysis were investigated. Recombinant human erythropoietin was applied subcutaneously in a dose of 75 IU/kg on 19 patients. Serum levels of transforming growth factor beta-1, interleukin 1-alpha, interleukin 3, interferon gamma, tumour necrosis factor alpha and erythropoietin, red blood cell parameters: red blood cell count, haemoglobin, haematocrit, and erythrocyte indices were determined before and after recombinant human erythropoietin single application. Transforming growth factor beta-1 serum levels were decreased after recombinant human erythropoietin (22.70 +/- 1.51 ng/ml versus 18.77 +/- 1.70 ng/ml (p < 0.01). None of the other investigated parameters was influenced significantly by recombinant human erythropoietin. Recombinant human erythropoietin in patients with chronic renal failure on chronic haemodialysis may influence anaemia not only through its stimulating effect on erythropoiesis, but also by direct oxygen-independent decrease of at least one of the negative regulators of erythropoiesis--the transforming growth factor beta.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Factor de Crecimiento Transformador beta
/
Eritropoyetina
/
Diálisis Renal
/
Fallo Renal Crónico
Tipo de estudio:
Etiology_studies
Límite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Arch Physiol Biochem
Asunto de la revista:
BIOQUIMICA
/
FISIOLOGIA
Año:
1998
Tipo del documento:
Article
País de afiliación:
Bulgaria
Pais de publicación:
Reino Unido